Re: Letter of Intent for Clinical Trial Services to be provided by Nordic Bioscience A/S (“NB”) to Radius Health, Inc. (“Radius”)Letter of Intent • August 1st, 2012 • Radius Health, Inc. • Blank checks
Radius and NB are parties to that certain Clinical Trial Services Agreement dated as of the March 29, 2011 (the “CTS Agreement”) and a certain Work Statement NB-1 under the CTS Agreement. Pursuant to Section 2.1 of the CTS Agreement, we have been negotiating the definitive terms of a certain Work Statement NB-2 under the CTS Agreement for the performance of a “Six Month Phase 2 Study of BA058 Presented as a Coated Transdermal Microarray Delivery System (BA058 sMTS) in the Treatment of Postmenopausal Women with Osteoporosis” (the “Study”). Work Statement NB-2 provides for payment by Radius to NB of both cash and equity compensation in consideration of the services provided by NB pursuant to such Work Statement NB-2, with the equity portion of such compensation to be made pursuant to an Amendment No. 1 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011. Radius has determined that it is required to take certain actions to comply with its Ce
Re: Amendment to March 29, 2011 Letter Agreement regarding understanding with respect to stock issuable in connection with services pursuant to a future Work Statement NB-2 between Nordic Bioscience Clinical Development VII a/s (“NB”) and Radius...Letter Agreement • August 1st, 2012 • Radius Health, Inc. • Blank checks
Radius and NB entered into the certain letter agreement dated March 29, 2011 concerning that certain Clinical Trial Services Agreement dated as of the March 29, 2011 (the “CTS Agreement”) and a Stock Issuance Agreement (the “SI Agreement”) pursuant to which Radius is issuing certain shares of Series A-5 Preferred Stock to NB, which shares entitle the holder to receive certain stock dividends payable in shares of Series A-6 Preferred Stock (the “March 29, 2011 Agreement”). The March 29, 2011 Agreement provided that if Radius and NB entered into a certain Work Statement NB-2 under the CTS Agreement for the performance of a “Six Month Phase 2 Study of BA058 Presented as a Coated Transdermal Microarray Delivery System (BA058 sMTS) in the Treatment of Postmenopausal Women with Osteoporosis” then NB shall be paid a portion of the purchase price for the Services that are the subject of such Work Statement NB-2 in cash and the balance shall be paid by issuance to NB of shares of Radius Series
